If you are on peptide therapy, or you have been thinking about it, today’s news out of Maryland is worth understanding correctly. On July 23, 2026, an FDA advisory committee voted to recommend that four widely used peptides be made available again through compounding pharmacies. The votes were close, the FDA’s own scientists argued against it, and nothing about what is legal today actually changed.
Here is what happened, and what it does and does not mean for patients.
What the committee actually voted on
The group that met is the Pharmacy Compounding Advisory Committee, or PCAC. It advises the FDA on which raw ingredients compounding pharmacies are allowed to work with. The specific question in front of them was whether seven peptides should be added to something called the Section 503A Bulk Drug Substances List.
That list matters more than the name suggests. A substance on it can be compounded by a licensed pharmacy for an individual patient without the ingredient itself having gone through full FDA drug approval. Off the list, a compounding pharmacy legally cannot touch it. In 2023 the FDA put several of these peptides into a category that effectively pulled them off the menu, which is why access has been so complicated since.
Seven peptides were nominated for review: BPC-157, KPV, TB-500, MOTS-c, emideltide (also called DSIP), semax, and epitalon. The meeting was split across two days. Thursday covered the first four. Friday covers the remaining three.
The Thursday results
All four peptides heard on day one were recommended for the list.
- BPC-157, nominated for ulcerative colitis, passed 8 to 6 with one abstention.
- KPV, nominated for inflammation, passed 8 to 6 with one abstention.
- TB-500, nominated for wound healing, passed.
- MOTS-c, nominated for obesity and osteoporosis, passed.
BPC-157 and KPV each got two separate votes to account for different chemical forms of the molecule. The committee did not release detailed tallies for TB-500 and MOTS-c.
Notice the margins. Eight to six with an abstention is not a mandate. That is a room that was genuinely divided, and it is worth being honest about that rather than reading the headline as a green light.
The FDA’s own scientists said no
This is the part most of the coverage is glossing over, and it is the part I find most interesting clinically.
Going into the meeting, the FDA’s briefing documents recommended against adding all seven peptides. Not some of them. All of them. Agency staff spent the day laying out the case: thin human evidence, unresolved safety questions, and in the case of KPV, no human studies at all.
Russell Wesdyk from the FDA raised what I think is the sharpest objection, and it has nothing to do with whether these compounds work. His point was about identity. You will see many different forms of these peptides all sold under the same name, which makes it nearly impossible to write a manufacturing standard for what a pharmacy is actually compounding. If two vials labeled BPC-157 do not contain the same molecule, no amount of clinical enthusiasm fixes that.
The committee members split along predictable lines. Dr. Brian Lee voted no and said the endorsement could be potentially harmful and that he could not in good conscience vote yes. On the other side, Dr. Kris Wusterhausen said that once you see the effects of BPC, you cannot unsee it.
That exchange is the whole debate in miniature. Clinicians who use these compounds see responses in their patients. Regulators want controlled human data and reproducible chemistry. Both positions are defensible. They are also not the same kind of evidence, and pretending otherwise does patients a disservice.
What this does not mean
I want to be very direct here, because I have already seen posts online this morning claiming peptides are legal again.
They are not. Three things have to be true before anything changes:
The vote is advisory only. PCAC recommends. The FDA decides. The agency usually follows its advisory committees, but it is not required to, and here the agency’s own staff took the opposite position from the panel. That is an unusual setup and it makes the outcome harder to predict than normal.
Rulemaking has to happen. Even with a full FDA yes, adding a substance to the 503A list requires formal notice-and-comment rulemaking. That means a proposed rule, a public comment period, review of those comments, and then a final rule. Realistically that is a year or more, not weeks.
Nothing is different today. What a compounding pharmacy can legally dispense this afternoon is exactly what it could dispense on Wednesday. If a vendor emails you this week saying the FDA just approved peptides and you should stock up, that is a sales pitch, not a regulatory update.
What is still pending
The committee reconvenes Friday for emideltide (DSIP), semax, and epitalon. Given how Thursday went, there is reason to think those votes could break the same direction, but the day one margins were narrow enough that I would not assume it.
We will update this post once those results are in.
How we are handling this at our clinic
Our approach does not change based on a non-binding vote, and I would be skeptical of any clinic whose approach does.
What we care about on our end is what is actually in the vial. Every peptide we use comes with a batch-specific certificate of analysis from an independent laboratory: identity and purity by HPLC, bacterial endotoxin testing to USP standards, heavy metals, and sterility. Not a certificate for the product line in general. For that specific lot. We review them before anything gets used, and if you want to see the documentation for what you are being given, ask and we will pull it.
That is paired with the parts that matter clinically. Baseline labs where they are indicated, a defined protocol with a start and a stop rather than an open-ended prescription, and follow-up to decide honestly whether something is doing anything for you. That applies to BPC-157, to MOTS-c, and to combination protocols like the BPC-157 and TB-500 stack.
Sourcing across this whole category is going to keep moving over the next year as the FDA works through the rulemaking. If ours changes, we will tell patients directly rather than quietly swapping and saying nothing.
What I would ask you to avoid is the untested end of the market. The single most common thing I see go wrong with peptides is not the peptide. It is a vial nobody has ever tested. No batch documentation, no purity figure, no endotoxin screen, no way to know whether what is printed on the label is what is in the glass.
That was the sharpest point raised at the hearing, and it is the one I agree with completely. Wesdyk was not arguing that these molecules do nothing. He was arguing that you cannot write a standard for a product whose contents vary from vial to vial. Whatever you think about how the committee voted, he is right about that, and it is why documentation is the first thing I would judge any source on.
If you are currently sourcing something on your own and want an honest conversation about it without a lecture, that is a conversation worth having. Bring the vial and whatever paperwork came with it. I would rather know what you are taking.
The bigger picture
My read, for whatever it is worth as someone who both practices emergency medicine and runs a wellness practice: this vote is directionally good news for patient access, and it is also a reminder that the evidence base here is thinner than the marketing suggests.
Those two things are both true. A peptide can be worth trying under supervision and still be under-studied. The people voting yes and the people voting no were largely arguing about which of those facts should carry more weight, not about whether the other one exists.
What would actually settle it is real trials. Until then, the honest position is supervised use, clear expectations, verified sourcing, and a willingness to stop something that is not working.
Have questions about peptide therapy or want to review what you are currently taking? Call us at (727) 274-1972 or book online at olympiaaesthetics.com/contact/. You can also read more about our peptide therapy programs.
This post covers a regulatory development and is general information, not medical advice. Peptide therapy is not appropriate for everyone. Individual candidacy is determined during a medical consultation.
